News
AbbVie joins a select group of big pharma groups working on psychedelic medicines, paying $65m on an option deal with Gilgamesh Pharma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback